A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/498 (2006.01) A61K 31/5377 (2006.01) A61K 31/541 (2006.01) A61P 1/00 (2006.01) A61P 3/10 (2006.01) A61P 17/00 (2006.01) A61P 17/06 (2006.01) A61P 19/02 (2006.01) A61P 21/00 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01) A61P 37/06 (2006.01) A61P 41/00 (2006.01) A61P 43/00 (2006.01) C07D 241/42 (2006.01) C07D 401/04 (2006.01) C07D 401/10 (2006.01) C07D 401/14 (2006.01) C07D 403/04 (2006.01) C07D 405/14 (2006.01)
Patent
CA 2690288
The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R; R2 is caryl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8 R3, R4, and R5 are each independently hydrogen or R9; R6 is hydrogen; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.
La présente invention porte sur un composé de la quinoxaline représenté par la formule (I) : dans laquelle R1 est carbocyclyle ou hétérocyclyle, l'un ou l'autre étant facultativement substitué par 1, 2, 3, 4 ou 5 R7 ; R2 est un carbocyclyle ou hétérocyclyle, l'un ou l'autre étant facultativement substitué par 1, 2, 3, 4 ou 5 R8 ; R3, R4, R5 et R6 sont chacun indépendamment hydrogène ou R9 ; et R7, R8 et R9 sont chacun indépendamment choisis parmi des substituants organiques et inorganiques, et sur leur utilisation dans la thérapie de maladies, en particulier des maladies à médiation par l'activité tyrosine kinase des kinases Janus, comprenant les kinases JAK-2 et JAK-3.
Furet Pascal
Gaul Christoph
Gerspacher Marc
Holzer Philipp
Pissot Soldermann Carole
Fetherstonhaugh & Co.
Novartis Ag
LandOfFree
Quinoxaline derivatives as inhibitors of the tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoxaline derivatives as inhibitors of the tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxaline derivatives as inhibitors of the tyrosine kinase... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1476598